Equibles does not estimate personal net worth.
Get an email with a short summary when Pediatrix Medical Group, Inc. publishes a filing, an earnings call transcript or a press release.
Get MD alertsMark S. Ordan is recorded as Chairman at Pediatrix Medical Group, Inc. (MD) since January 1, 2023 and CEO at Pediatrix Medical Group, Inc. (MD). The newest filing on record that lists Mark S. Ordan as CEO at Pediatrix Medical Group, Inc. (MD) is dated March 27, 2026. Pediatrix Medical Group, Inc. reported in an 8-K filed January 14, 2025 that Mark S. Ordan was appointed Chief Executive Officer, effective January 12, 2025. Pediatrix Medical Group, Inc. reported in an 8-K filed December 16, 2022 that Mark S. Ordan was appointed Executive Chair of the Board, effective January 1, 2023. Pediatrix Medical Group, Inc. reported in an 8-K filed December 16, 2022 that Mark S. Ordan was terminated as Chief Executive Officer, effective January 1, 2023. The proxy statement of Pediatrix Medical Group, Inc. reports total compensation of $14,140,217 for Mark S. Ordan in fiscal 2025, including a base salary of $970,014. Disclosed compensation is on record for 4 fiscal years. Mark S. Ordan has spoken on 1 earnings call across 1 company, most recently for Pediatrix Medical Group, Inc. on August 5, 2025. Pediatrix Medical Group, Inc. is classified in the Medical Care Facilities industry within the Healthcare sector. Other leadership on record at Pediatrix Medical Group, Inc. includes James D. Swift, M.D. (CEO, COO and Board Member), Guy P. Sansone (Chairman and Board Member), Kasandra Rossi (CFO) and 7 others.
“Effective on January 12, 2025 (the "Effective Date"), the Board of Directors (the "Board") of Pediatrix Medical Group, Inc., a Florida corporation (the "Company"), appointed Mr. Mark S. Ordan to serve as the Company's Chief Executive Officer and principal executive officer, succeeding Dr. James D. Swift.”
“On December 15, 2022, the Board of Directors (the "Board") of Pediatrix Medical Group, Inc., a Florida corporation (the "Company"), appointed James D. Swift, M.D., as the Company's Chief Executive Officer and principal executive officer to succeed Mr. Mark S. Ordan, who has been appointed as the Executive Chair of the Board, each effective January 1, 2023.”
“Also with me today is Kasandra Rossi, our Chief Financial Officer. Our second quarter results, including adjusted EBITDA of just over $73 million exceeded our expectations.”
2023-01-01–present
Start not stated–present
Last confirmed March 27, 2026
Proxy statement
Start not stated–2024-03-28
Last confirmed by a filing; no departure on record
Start not stated–2022-04-01
Last confirmed by a filing; no departure on record
Start not stated–2023-01-01
Medical Care Facilities · Healthcare
CEO, Chairman
2023-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Pediatrix Medical Group, Inc. (MD) | Chief Executive Officer | $970,014 | $14,140,217 |
| 2022 | Pediatrix Medical Group, Inc. (MD) | Executive Chair (Former Chief Executive Officer) | $1,000,000 | $4,655,746 |
| 2021 | Pediatrix Medical Group, Inc. (MD) | Executive Chair (Former Chief Executive Officer) | $1,000,000 | $6,848,969 |
| 2020 | Pediatrix Medical Group, Inc. (MD) | Executive Chair (Former Chief Executive Officer) | $471,014 | $6,438,682 |
